A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
INTEGRA LIFESCIENCES HOLDINGS CORP
IART
$1.5B
Mkt Cap
$19.79
+6.63%
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a 5-year average return on invested capital (ROIC) of -0.6%. This is below average and may indicate limited pricing power.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a market capitalization of $1.8B. It is classified as a small-cap stock.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.01%.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported annual revenue of $1.6 billion in its most recent fiscal year, based on SEC EDGAR filings.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a net profit margin of -31.6%. The company is currently unprofitable.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) generated $-31 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ITEM 1. BUSINESS Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat (“ENT”). We are the world leader in neurosurgery and one of the top three providers in the U.S. in instruments used in precision, specialty, and general surgical procedures.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.6B | 1.6B | 1.6B | 1.5B | 1.6B | 1.5B |
| Net Income | -496M | -516M | -6.9M | 68M | 181M | 169M |
| EPS | $-5.37 | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 |
| Free Cash Flow | 4.1M | -31M | 25M | 73M | 222M | 264M |
| ROIC | -24.0% | -25.3% | 1.2% | 4.2% | 9.2% | 7.5% |
| Gross Margin | - | 50.9% | 54.8% | 57.4% | 62.3% | 61.2% |
| Debt/Equity | 0.72 | 0.87 | 0.98 | 0.60 | 0.55 | 0.59 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -466M | -493M | 28M | 112M | 239M | 197M |
| Operating Margin | -28.4% | -30.2% | 1.8% | 7.2% | 15.3% | 12.8% |
| ROE | -47.6% | -39.9% | -0.4% | 4.0% | 10.3% | 10.6% |
| Shares Outstanding | 92M | 77M | 77M | 81M | 84M | 85M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 797M | 883M | 992M | 1.2B | 1.5B | 1.5B | 1.4B | 1.5B | 1.6B | 1.5B | 1.6B | 1.6B | 1.6B |
| Gross Margin | 62.0% | 63.0% | 64.8% | 63.3% | 61.2% | 62.8% | 62.0% | 61.2% | 62.3% | 57.4% | 54.8% | 50.9% | N/A |
| R&D | 44M | 51M | 58M | 63M | 78M | 80M | 77M | 93M | 101M | 104M | 115M | 99M | 98M |
| SG&A | 376M | 416M | 456M | 624M | 691M | 688M | 595M | 637M | 616M | 657M | 717M | 700M | 696M |
| EBIT | 68M | 80M | 115M | 45M | 111M | 94M | 151M | 197M | 239M | 112M | 28M | -493M | -466M |
| Op. Margin | 8.5% | 9.0% | 11.6% | 3.8% | 7.5% | 6.2% | 11.0% | 12.8% | 15.3% | 7.2% | 1.8% | -30.2% | -28.4% |
| Net Income | 34M | -3.5M | 75M | 65M | 61M | 50M | 134M | 169M | 181M | 68M | -6.9M | -516M | -496M |
| Net Margin | 4.3% | -0.4% | 7.5% | 5.4% | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% | -30.1% |
| Non-Recurring | 0 | 0 | -1.8M | -7.0M | -1.4M | -1.8M | 0 | 42M | 644K | 0 | 0 | 511M | 511M |
| Returns on Capital | |||||||||||||
| ROIC | 5.5% | 4.1% | 6.1% | 2.2% | 4.6% | 3.6% | 7.2% | 7.5% | 9.2% | 4.2% | 1.2% | -25.3% | -24.0% |
| ROE | 4.8% | -0.5% | 9.4% | 7.2% | 5.2% | 3.6% | 9.1% | 10.6% | 10.3% | 4.0% | -0.4% | -39.9% | -47.6% |
| ROA | 2.1% | -0.2% | 4.2% | 2.6% | 1.9% | 1.6% | 3.9% | 4.6% | 4.7% | 1.8% | -0.2% | -13.5% | -13.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 79M | 105M | 116M | 115M | 200M | 231M | 204M | 312M | 264M | 140M | 129M | 50M | 71M |
| Free Cash Flow | 41M | 71M | 69M | 71M | 122M | 162M | 165M | 264M | 222M | 73M | 25M | -31M | 4.1M |
| Owner Earnings | 18M | 31M | 26M | 4.0M | 68M | 101M | 114M | 220M | 183M | 67M | 41M | -28M | -396M |
| CapEx | 38M | 33M | 47M | 44M | 78M | 70M | 39M | 48M | 42M | 67M | 104M | 81M | 67M |
| Maint. CapEx | 46M | 59M | 73M | 89M | 111M | 109M | 70M | 56M | 54M | 53M | 64M | 60M | 445M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14M | 41M | 22M | 0 |
| D&A | 46M | 59M | 73M | 89M | 111M | 109M | 70M | 56M | 54M | 53M | 64M | 60M | 445M |
| CapEx/OCF | 48.2% | 31.9% | 40.7% | 38.0% | 38.9% | 30.0% | 19.1% | 15.4% | 16.0% | 47.8% | 80.7% | 161.6% | 94.3% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 100M | 0 | 125M | 275M | 52M | 221K | 221K |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 1.8% | N/A | 2.7% | 7.8% | 3.0% | 0.0% | 0.0% |
| Stock-Based Comp | 15M | 15M | 17M | 22M | 21M | 21M | 20M | 36M | 28M | 20M | 24M | 19M | 22M |
| Debt Repayment | 3.2M | 1.4M | 184M | 19M | 5.0M | 0 | 24M | 249K | 0 | 7.9M | 0 | 575M | 575M |
| Balance Sheet | |||||||||||||
| Net Debt | 277M | 414M | 563M | 1.7B | 784M | 833M | 542M | 480M | 529M | 648M | 1.2B | 640M | 490M |
| Cash & Equiv. | 72M | 48M | 102M | 175M | 139M | 199M | 470M | 513M | 457M | 276M | 246M | 235M | 266M |
| Long-Term Debt | 413M | 482M | 665M | 1.8B | 900M | 878M | 878M | 844M | 775M | 775M | 760M | 727M | 717M |
| Debt/Equity | 0.60 | 0.68 | 0.79 | 1.91 | 0.67 | 0.73 | 0.67 | 0.59 | 0.55 | 0.60 | 0.98 | 0.87 | 0.72 |
| Interest Coverage | 3.1 | 3.4 | 4.5 | 1.3 | 1.7 | 1.7 | 2.1 | 3.9 | 4.8 | 2.2 | 0.4 | -5.7 | -5.7 |
| Equity | 704M | 751M | 840M | 962M | 1.4B | 1.4B | 1.5B | 1.7B | 1.8B | 1.6B | 1.5B | 1.0B | 1.0B |
| Total Assets | 1.6B | 1.8B | 1.8B | 3.2B | 3.1B | 3.3B | 3.6B | 3.8B | 3.9B | 3.8B | 4.0B | 3.6B | 3.6B |
| Total Liabilities | 883M | 1.0B | 968M | 2.2B | 1.7B | 1.9B | 2.1B | 2.1B | 2.1B | 2.2B | 2.5B | 2.6B | 2.5B |
| Intangibles | 413M | 604M | 561M | 1.2B | 1.1B | 1.0B | 989M | 1.1B | 1.1B | 1.1B | 1.2B | 1.1B | 1.1B |
| Retained Earnings | 315M | 146M | 220M | 285M | 348M | 399M | 532M | 699M | 879M | 947M | 940M | 423M | 419M |
| Working Capital | 403M | 299M | 372M | 473M | 513M | 527M | 836M | 814M | 841M | 751M | 160M | 704M | 825M |
| Current Assets | 529M | 438M | 495M | 822M | 775M | 858M | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B | 1.2B | 1.2B |
| Current Liabilities | 126M | 139M | 124M | 349M | 263M | 331M | 401M | 340M | 321M | 307M | 922M | 456M | 347M |
| Per Share Data | |||||||||||||
| EPS | 0.52 | -0.03 | 0.47 | 0.82 | 0.72 | 0.58 | 1.57 | 1.98 | 2.16 | 0.84 | -0.09 | -6.74 | -5.37 |
| Owner EPS | 0.28 | 0.22 | 0.17 | 0.05 | 0.81 | 1.16 | 1.34 | 2.58 | 2.19 | 0.83 | 0.54 | -0.36 | -4.29 |
| Book Value | 10.67 | 5.34 | 5.29 | 12.19 | 16.29 | 16.37 | 17.76 | 19.73 | 21.59 | 19.69 | 20.03 | 13.62 | 11.31 |
| Cash Flow/Share | 1.20 | 0.74 | 0.73 | 1.45 | 2.36 | 2.67 | 2.39 | 3.66 | 3.16 | 1.74 | 1.68 | 0.66 | -0.55 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 66.0M | 140.8M | 158.6M | 79.0M | 84.4M | 86.6M | 85.3M | 85.4M | 83.6M | 80.6M | 77.2M | 76.6M | 92.2M |
| Valuation | |||||||||||||
| P/E Ratio | 47.3 | N/A | 45.5 | 60.0 | 61.6 | 101.2 | 42.2 | 34.7 | 25.6 | 52.3 | N/A | N/A | -3.7 |
| P/FCF | 39.1 | 66.5 | 98.2 | 54.6 | 30.7 | 31.4 | 34.2 | 22.2 | 20.8 | 48.5 | 69.0 | N/A | 447.1 |
| EV/EBIT | 27.8 | 35.1 | 33.4 | 121.3 | 42.5 | 63.7 | 37.7 | 29.2 | 20.8 | 36.7 | 91.7 | N/A | N/A |
| Price/Book | 2.3 | 3.2 | 4.0 | 4.0 | 2.7 | 3.6 | 3.7 | 3.5 | 2.6 | 2.2 | 1.1 | 0.9 | 1.7 |
| Price/Sales | 1.8 | 2.3 | 3.0 | 3.2 | 3.3 | 3.2 | 3.1 | 3.8 | 3.1 | 2.4 | 1.4 | 0.8 | 1.1 |
| FCF Yield | 2.6% | 3.0% | 2.0% | 1.8% | 3.3% | 3.2% | 2.9% | 4.5% | 4.8% | 2.1% | 1.4% | -3.2% | 0.2% |
| Market Cap | 1.6B | 2.4B | 3.4B | 3.9B | 3.7B | 5.1B | 5.6B | 5.9B | 4.6B | 3.5B | 1.7B | 967M | 1.8B |
| Avg. Price | 21.57 | 29.46 | 37.39 | 47.66 | 57.87 | 55.35 | 50.63 | 69.16 | 57.12 | 46.56 | 28.63 | 16.25 | 19.79 |
| Year-End Price | 24.37 | 33.76 | 42.76 | 49.17 | 44.33 | 58.68 | 66.21 | 68.77 | 55.22 | 43.93 | 22.33 | 12.62 | 19.79 |
INTEGRA LIFESCIENCES HOLDINGS CORP passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 57.3%. At current prices, the estimated annualized return to fair value is -15.5%.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a debt-to-equity ratio of 0.87. This indicates moderate leverage.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported earnings per share (EPS) of $-6.74 in its most recent fiscal year.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a return on equity (ROE) of -39.9%. A negative ROE may indicate losses or negative equity.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a 5-year average gross margin of 57.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for INTEGRA LIFESCIENCES HOLDINGS CORP (IART), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) has a book value per share of $13.62, based on its most recent annual SEC filing.